IP Library › Granted Patent US 10,647,752
Granted Patent B2
US 10,647,752 · App. 15/761,828 · Granted May 12, 2020

Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1

Inventors: Zakia Belaid-Choucair (Paris, FR); Olivier Hermine (Paris, FR); Matthieu Montes (Paris, FR); Carmen Garrido-Fleury (Dijon, FR); Renaud Seigneuric (Dijon, FR); Guillaume Marcion (Dijon, FR)
Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale); Fondation Imagine; Assistance Publique-Hopitaux de Paris (APHP); Université Paris Descartes; Centre National de la Recherche Scientifique (CNRS); Université de Bourgogne; CNAM—Conservatoire National des Arts at Metier
C07K14/475A61K38/1866A61K39/3955A61P35/00C07K14/5759C07K14/705C07K14/72C07K16/22A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,647,752
App. No.
15/761,828
Granted
May 12, 2020
Kind
B2
Abstract

The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.

Claims (6)

1. An isolated, a synthetic or a recombinant polypeptide capable of inhibiting the binding between leptin and NRP-1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:3 (ENLRDLLHVLAFSKSCHLPWASGLETL) or SEQ ID NO:4 (EGNKPVLFOGNTNPTDVYVAVFPK), and wherein the polypeptide is fused to at least one heterologous polypeptide.

2. A nucleic acid encoding the polypeptide fused to the at least one heterologous polypeptide of claim 1 .

3. The nucleic acid of claim 2 which is included in a suitable vector.

4. An isolated host cell comprising the nucleic acid of claim 2 .

5. A pharmaceutical composition comprising the polypeptide fused to the at least one heterologous polypeptide of claim 1 or a nucleic acid encoding the polypeptide fused to the at least one heterologous polypeptide.

6. The nucleic acid of claim 3 wherein the vector is a plasmid, a cosmid, an episome, an artificial chromosome, a phage or a viral vector.

Assignments (3)
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 056958/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: BELAID-CHOUCAIR, ZAKIA; HERMINE, OLIVIER; MONTES, MATTHIEU; GARRIDO-FLEURY, CARMEN; SEIGNEURIC, RENAUD; MARCION, GUILLAUME
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); FONDATION IMAGINE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; UNIVERSITE DE BOURGOGNE; CNAM - CONSERVATOIRE NATIONAL DES ARTS ET METIER
Reel/Frame 045596/0254 →
Priority Claims (1)
EP 15306471 · Sep 22, 2015 · regional
Continuity (1)
Related Publication 20180230189A1 · Aug 16, 2018